Connect with us
Advertisement
Advertisement

Health

Gene study on depression’s origins

Published

on

HUNDREDS of genes have been newly linked to depression, shedding light on the origins of the condition and highlighting personality types that could be at risk.

The international study, involving more than two million people, is the largest of its kind. It could inform treatments for the condition, which affects one in five people in the UK and is the leading cause of disability worldwide.

Scientists led by the University of Edinburgh studied information pooled from three large datasets of anonymised health and DNA records and pinpointed 269 genes that were linked to depression.

They also used an innovative statistical method to identify sections of DNA that were common in people with depression and in those who adopted lifestyle behaviours such as smoking.

The findings suggest that depression could be a driving factor leading some people to smoke, but more research is needed to explain why, the team says.

Results also show that neuroticism – a tendency to be worried or fearful – could lead people to become depressed, which could shed light on personality factors that put people at risk. The statistical approach – known as Mendelian randomisation – allows scientists to look at how a condition impacts on behaviour, while ruling out other influences such as age or income.

Anonymised data, used with donor consent, is held by UK Biobank, the personal genetics and research company 23andMe and the Psychiatry Genomics Consortium.

Experts say that the study reflects the importance of data science in understanding mental health.

The study, published in Nature Neuroscience, was funded by the MRC and Wellcome.

Professor Andrew McIntosh, of the University of Edinburgh’s Centre for Clinical Brain Sciences, who led the research, said: “These findings are further evidence that depression is partly down to our genetics.

“We hope the findings will help us understand why some people are more at risk of depression than others, and how we might help people living with depression and anxiety more effectively in future.”

Sophie Dix, Director of Research at mental health charity MQ, who was not involved in the research, said: “This study adds to the weight of evidence that genes are one of the key risk factors in depression, which is also impacted by life events such as social environment and trauma. The value of this could really be seen when looking into the development of personalised treatments – a welcome step, given the dearth of innovation in identifying new approaches. We have seen very little advancement in nearly 50 years for people living with depression and right now the avenues available are not working for everyone.

“The power of this big genetic study is that it can point to systems in the brain which adds to our currently limited understanding in this area. By increasing our understanding of these systems, and how the social environment affects biological risk factors, we can begin to identify new targets for treatments that could help the millions of people worldwide affected by depression.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Proton therapy centre officially opened

Published

on

HEALTH Minister Vaughan Gething has set out his vision for cutting edge precision medicine to improve health and deliver a sustainable future for NHS Wales.

During, a visit to the Rutherford Cancer Centre in Newport, Mr Gething announced new strategies to transform pathology and precision therapeutics in Wales.

He said: “To address future challenges from the increasing burden of disease we must focus more on prevention, early detection and personalised targeted treatments. Precision medicine will increasingly support a more personalised approach to health and care.

“In Wales, we are already making progress in the field of precision medicine and I am confident that we can be a global player in the race to harness its potential. NHS Wales is on the cusp of realising the significant benefits that can be delivered by advances in precision medicine for patients by offering the right test or treatment at the right time.

“Our long term plan ‘A Healthier Wales’ recognises the importance of moving towards earlier detection and intervention to prevent illness and prolong independence.”

One of the first patients in the UK to receive high-energy proton beam therapy has today praised UK oncologists for embracing proton beam therapy and the transformative effects it has had on his treatment.

Ryan Scott, 23, from Cardigan in Wales, underwent treatment for a brain tumour (grade 1 craniopharyngioma) at the Rutherford Cancer Centre South Wales in Newport as part of NHS Wales’ proton beam therapy treatment pathway for adults.

Ryan Scott said: “I was very pleased when my consultant recommended proton beam therapy and told me that it was available close to home in South Wales. I was due to be treated with proton beam therapy over the course of eight weeks in the United States, a disruption I was not looking forward to. Happily, however, the agreement between NHS Wales and the Rutherford Cancer Centres was struck just in time for me to be treated a short drive from home.

“The process of undergoing proton beam therapy was much better than anticipated. There have been hardly any side effects and being able to sleep in my bed after a day’s treatment is a real plus.”

Mr Gething explained the Welsh Government had a clear vision for harnessing technology to deliver precision medicine in diagnostics and therapy that will ensure a sustainable future for NHS Wales.

“The Rutherford Cancer Centre in Newport, which was the first facility in the UK to offer proton beam therapy for cancer patients, is an excellent example of the development of new cancer therapies, here in Wales. It’s a perfect illustration of how we are working collaboratively to deliver technological innovations to improve treatment,” he said.

“Today I have published our Statement of Intent for Advanced Therapeutic Medicinal Products, which sets out how we will deliver precision therapeutics, like new cell therapies, in Wales.

“Alongside this, I have published a Statement of Intent to transform pathology services. All this builds on our recent investment in diagnostic services such as the new Imaging Academy for Wales.

“In this financial year, I am pleased to provide additional funding of £2.3m to support the delivery of new genetic tests together with a further £2m to support national plans for transforming diagnostic, health science and advanced therapeutic medical services in NHS Wales.”

Andrew Goodall, chief executive of NHS Wales, also attended today’s official opening.

The centre is part of a nationwide network that provides state-of-the-art cancer services including imaging, chemotherapy, immunotherapy, radiotherapy and high energy proton beam therapy.

The Newport centre was recently approved by the Welsh Health Specialised Services Committee (WHSSC) to provide high energy proton beam therapy to adult patients referred from the NHS in Wales, the centre also treated the first patient in the UK with proton beam therapy in April last year.

Mike Moran, chief executive of Proton Partners International which operates the Rutherford Cancer Centres, said: “It is gratifying to see UK oncologists becoming increasingly aware of proton therapy and embracing the treatment. Our collaborative partnership with the NHS in Wales means that adult patients have an option to be treated closer to home.”

“I am delighted by the support we have received from the Health Minister, the Welsh Government, the Wales Life Sciences Investment Fund and the NHS in Wales which has meant that Wales has been the pioneer in proton beam therapy in the UK. Patient demand is increasing and it is encouraging that the UK is beginning to catch up with Europe in the provision of this therapy.”

Continue Reading

Health

Bounty sold mums’ and babies’ data

Published

on

THE INFORMATION Commissioner’s Office (ICO) has fined Bounty (UK) Limited £400,000 for illegally sharing personal information belonging to more than 14 million people.

An ICO investigation found that Bounty, a pregnancy and parenting club, collected personal information for the purpose of membership registration through its website and mobile app, merchandise pack claim cards and directly from new mothers at hospital bedsides.

But the company also operated as a data broking service until April 30, 2018, supplying data to third parties for the purpose of electronic direct marketing.

Bounty breached the Data Protection Act 1998 by sharing personal information with a number of organisations without being fully clear with people that it might do so.

The company shared approximately 34.4 million records between June 2017 and April 2018 with credit reference and marketing agencies, including Acxiom, Equifax, Indicia and Sky.

These organisations represented the four largest recipients out of a total of 39 organisations which Bounty confirmed it shared personal data with.

The personal information shared was not only of potentially vulnerable, new mothers or mothers-to-be but also of very young children, including the birth date and sex of a child.

Steve Eckersley, ICO’s Director of Investigations, said: “The number of personal records and people affected in this case is unprecedented in the history of the ICO’s investigations into data broking industry and organisations linked to this.

Continue Reading

Health

Get Mouthy About Cancer

Published

on

THE HEAD and Neck Cancer Foundation (HNCF) is calling all Brits to ask their dentists to conduct mouth cancer screens at their next appointment. This should be routinely included within the price of a dental check-up and should take no more than one minute.

Consumer research conducted by HNCF in partnership with YouGov – as part of its Get Mouthy About Cancer campaign – shows that we could all be doing more to specifically drive early diagnosis of mouth cancers.

Early detection is paramount to improving patient outcomes – as these types of cancers can be extremely aggressive, disfiguring and life-limiting.

HNCF’s research asked people in Wales how often they have routine dental check-ups and if they are receiving mouth cancer screening.

6% of people in Wales admit to never going to the dentist for a check-up and a further 3% said they do not recall the last time they went to the dentist

Only half of the Welsh population visit the dentist every six months for a routine check-up.

Shockingly, over half (51%) of those in Wales stated that they were not sure if their dentist had carried out a mouth cancer check at their last check-up

When looking nationally at overall awareness of mouth cancer screening – nearly three-quarters of all Brits stated their dentist does not do a regular mouth cancer screen, or they are unaware of it being done during their last check-up. Which means the vast majority of us are missing out on this simple routine and potentially life-saving screen.

Michelle Vickers, CEO at The Head and Neck Cancer Foundation commented on the findings: “As a nation, we are regrettably unaware that our dentists can play a huge role in oral cancer detection and be routinely screening for signs of mouth cancer during check-ups. Dentists are taught to do this as part of their standard oral check-up process. If people were screened they would know – as the tongue is held to either side of the mouth and the dentist is likely to follow the gums for signs of abnormal growth. We are asking everyone to ask their dentist for a routine screen the next time they visit – it’s really that simple.

“We’ve introduced our Get Mouthy About Cancer campaign because we all hear so often (and know how) to check our boobs or balls – but I bet the majority of people are unaware of what they’re looking for in their mouth! 31 people are diagnosed with head and neck cancers each day in the UK – so it’s time to get talking about what to look for. We brush our teeth daily – just an extra 30-60 seconds to check oral health could save your life!”

To find out how to check please watch HNCF’s video: http://bit.ly/HNCFWales. Once you’ve seen this video you will know whether your dentist is checking your mouth, or not, and how to check yourself at home.

Professor Mark McGurk, world-renowned surgeon and founder of HNCF added: “We want everyone to be having a conversation about mouth cancers. By bringing routine mouth checks front-of-mind and putting it on the agenda – we will raise awareness, raise the number of early detections and reduce the number of people facing stage two and three mouth cancers.”

For those patients who do detect mouth cancer early, technological and medical innovation means that treatment can now be offered in a much less invasive manner, by using the Sentinel Node Biopsy technique (SNB). SNB is an alternative and significantly less invasive treatment for dealing with head and neck cancers. The fluorescent camera and technology locates the nodes in the neck that will contain migrating cancer cells so that these can be targeted and removed – this saves over 70% of patients with early disease from a neck dissection. It spares vital glands and helps patients get back to a normal life more quickly, compared to traditional neck dissection techniques.

SNB has been endorsed by the National Institute for Health and Care Excellence (NICE), is fully adopted in Denmark and the Netherlands, and is growing in deployment across Europe and the US. This practice, pioneered by Professor Mark McGurk, is the result of 15 years’ development and is based on the findings of nearly 500 cases.

HNCF works to educate and train both surgeons and nurses around the UK on this treatment and state-of-the-art technology, to bring a better outcome and time-saving treatment to oral cancer patients.

Continue Reading

Trending

FOLLOW US ON FACEBOOK